Mao M, Carpenter TO, Whyte MP, et al. - In the present study, the researchers sought to provide linear growth curves for children with X-linked hypophosphatemia (XLH), 1-14 years of age, from birth to early adolescence. Pre-treatment data have been obtained from three interventional trials: two phase 2 trials (UX023CL201, UX023CL205) and a phase 3 trial (UX023-CL301). Two hundred twenty-eight patients (132 girls, 96 boys) with 2,381 height measurements were involved. According to findings, children with XLH demonstrate reduced height gain by 1 year of age and subsequently remain below population norms. Such data will assist in assessing therapeutic interventions on linear growth for pediatric XLH.